Shire Plc Bets to Double Sales on Rare Diseases? Drugs Network M?dica, Argentina - Nov 18, 2008 Rare diseases pathologies affect less than 50000 patients a year. Human Genetic Therapies would be a key driver by 2015. By the end of the year HGT sales ...SHPGY
Hudak calls on province to fund ailing boy's treatment St. Catharines Standard, Canada - Nov 21, 2008 Niagara West-Glanbrook MPP Tim Hudak has taken up the fight to fund treatment for a local boy with a rare genetic disorder. On Thursday, Hudak read a ...
UPDATE: Shire Aims To Grow Sales In Mid-Teens Range By 2015 EasyBourse.com, France - Nov 18, 2008 Basingstoke, England-based Shire stepped into the market for rare genetic diseases with the 2005 acquisition of US biotech company Transkaryotic Therapies ...SHPGY
Recent News and Articles on the Keywords: elaprase + rare + disorder Related to the article below (Last Update: 8/5/2008)
Canada should follow the US example on 'orphan' diseases Globe and Mail, Canada - Jul 17, 2008 Rare disorders are those that affect fewer than one in every 2000 people. There are an estimated 7000 such diseases in Canada and three in every four touch ...
Idursulfase for the treatment of mucopolysaccharidosis II - LA Clarke - Expert Opin. Pharmacother., 2008 - Expert Opinion ...Elaprase ? (Shire Human Genetic Therapies, Inc.), recombinant human idursulfase ... largest
single studies performed for a rare lysosomal disorder so far ...
[CITATION] International Approvals: Tysabri, Elaprase, Invega Y Waknine
New drug and biological product approvals, 2006. - K Traynor - American Journal of Health-System Pharmacy, 2007 - pt.wkhealth.com ... Idursulfase, marketed by Shire as Elaprase, was licensed in July for the treatment
of Hunter's syndrome, a rare lysosomal storage disorder that primarily ... -
Initial report from the Hunter Outcome Survey. Article JE Wraith, M Beck, R Giugliani, J Clarke, R Martin … - geneticsinmedicine.org ... development of recombinant human I2S (Elaprase, idursulfase, Shire ... of effective treat-
ment for rare diseases is ... natural history of the disease combined with ...
Enzyme reconstitution/replacement therapy for lysosomal storage diseases. - TA Burrow, RJ Hopkin, ND Leslie, BT Tinkle, GA … - Current Opinion in Pediatrics, 2007 - co-pediatrics.com ... administered as a 0.5 mg/kg weekly infusion (Elaprase package insert ... Private
organizations (eg the National Organization for RareDisorders and support groups ...
AUTHOR AND EDITOR INFORMATION N Braverman - emedicine.com ... of Hunter syndrome and to monitor long-term treatment effects of Elaprase. ... National
Organization for RareDisorders, Inc (NORD) 55 Kenosia Ave PO Box 1968 ... -
AUTHOR AND EDITOR INFORMATION - J Baloghova - emedicine.com ... Drug Name, Idursulfase (Elaprase). ... for patients and the medical community: The National
MPS Society, National Organization for RareDisorders, and National Tay ... -
Source: Google Scholar
Elaprase Approved for Rare Genetic Disorder
MONDAY, July 24 (HealthDay News) -- Elaprase (idursulfase) was approved Monday by the U.S. Food and Drug Administration as the first drug to treat Hunter syndrome, a rare, inherited disease that can cause premature death.
People with Hunter syndrome, which affects about one of every 65,000 to 132,000 births, cannot break down the body's complex sugars. Symptoms include stunted growth, joint stiffness, and coarse facial features. More severe effects include respiratory, cardiac and neurological problems, enlargement of the liver and spleen, and death, the FDA said in a statement.
Elaprase was approved as an orphan drug, meaning it was developed to treat a condition that affects fewer than 200,000 people. Such approval gives the Massachusetts-based manufacturer, Shire Human Genetic Therapies Inc., seven years of exclusive marketing rights.
Approval was granted following a 96-patient study that found treated patients were able to walk an average of 38 yards more in six minutes than untreated participants, the FDA said.
But some patients did suffer severe hypersensitivity reactions, prompting the agency to advise that "appropriate medical support should be readily available when Elaprase is administered."
